A
BCEL
vs
S&P 500
S&P 500
Over the past 12 months, BCEL has underperformed S&P 500, delivering a return of 0% compared to the S&P 500's +14% growth.
Stocks Performance
BCEL vs S&P 500
Performance Gap
BCEL vs S&P 500
Performance By Year
BCEL vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Atreca Inc
Glance View
Atreca, Inc. is a biopharmaceutical company. The company is headquartered in San Carlos, California and currently employs 134 full-time employees. The company went IPO on 2019-06-20. The firm use its platform to discover and develop antibody-based immunotherapeutic to treat a range of solid tumor types. The firm's lead product candidate, ATRC-101, is a monoclonal antibody with a mechanism of action and target derived from an antibody identified using its discovery platform. Its platform enables it to interrogate an active B cell response within an individual cancer patient to identify antibody-target pairs, which enable them to develop antibody-based product candidates to treat patients with solid tumors. ATRC-101 reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal and breast cancer samples from multiple patients. APN-122597 is its other product candidate. The firm's Immune Repertoire Capture (IRC) technology generates natively paired heavy and light chain sequences of the antibodies expressed by single B cells isolated from patient samples.